• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy

by July 18, 2024
written by July 18, 2024

Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy.

Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment to market.

The FDA’s recommendation came after Agenus presented results from its Phase 2 study, revealing a 19.4% overall response rate (ORR) and a 90% 6-month survival rate for the 75mg dosage of BOT/BAL.

However, concerns about the therapy’s survival benefits led to a sharp sell-off of Agenus stock, which had seen significant gains earlier in the year.

Dr. Steven O’Day, Agenus’ chief medical officer, emphasized the company’s determination to advance BOT/BAL, including plans to incorporate a BOT monotherapy arm in its upcoming Phase 3 trial.

This strategic move aims to address FDA concerns and pave the way for future regulatory approval.

Financial and analyst insights

Despite the stock’s recent downturn, analysts previously projected a bullish outlook for Agenus, with a consensus “buy” rating and an average price target of $39 per share.

The company’s financial resilience, including ending the first quarter with $52.9 million in cash, underscores its ability to navigate regulatory challenges while advancing its clinical pipeline.

Agenus to meet with European regulators

Looking ahead, Agenus plans strategic engagements with European regulators in the third quarter of 2024 to discuss regulatory pathways for BOT/BAL.

Additionally, the company will present compelling data on the therapy’s efficacy in treating Sarcoma at a prestigious European medical oncology event in September, highlighting its commitment to addressing unmet medical needs.

The FDA’s decision represents a critical juncture for Agenus as it strives to balance scientific innovation with regulatory scrutiny.

While the setback underscores the challenges inherent in drug development, Agenus remains steadfast in its mission to deliver innovative treatments that can potentially transform patient outcomes in oncology.

The post Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
next post
Domino’s Pizza stock crashes as American consumer struggles with rising food prices

related articles

Asian markets close: Nikkei, Kospi down; Sensex closes...

May 19, 2025

Qualcomm unveils AI chips for data centres with...

May 19, 2025

Best crypto to buy now: Bitcoin Pepe leads...

May 19, 2025

JPMorgan cuts Netflix rating, citing balanced risk-reward post-rally;...

May 19, 2025

Bitcoin ETF open interest dips 5% to $29.47B...

May 19, 2025

US stocks slip in the red on Monday:...

May 19, 2025

Should Klarna IPO remain on watch list after...

May 19, 2025

Why this brokerage downgraded UnitedHealth’s rating to ‘hold’

May 19, 2025

Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint...

May 19, 2025

Cathie Wood says Trump’s tariffs could unlock tech...

May 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Holo Stock Analysis: Market Volatility and Future Forecasts

    September 3, 2024
  • Business is good in ‘Vacationland.’ It would be even better with more housing.

    August 5, 2024
  • Trump warns US approaching ‘World War III territory’ under Biden-Harris admin: ‘Clowns’

    September 5, 2024
  • WH may reverse decision to kill Biden-Maduro oil deal, apply tariffs instead to avoid hurting US firms

    March 20, 2025
  • Unknown drone fleet breached US military base airspace in Virginia for 17 straight days: report

    October 13, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,723)
  • Investing (624)
  • Stock (773)

Latest Posts

  • On-Balance Volume (OBV) in Trading Explained

    September 19, 2024
  • Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint with Foxconn

    May 19, 2025
  • Trump downplays China-Russia-Iran nuclear talks, says they may discuss ‘de-escalation’

    March 13, 2025

Recent Posts

  • Trump now speaking with Russia’s Putin about ending Ukraine war

    March 18, 2025
  • AUDUSD and AUDNZD: AUDUSD has a chance to start a recovery

    July 26, 2024
  • Vance visits Capitol Hill to urge senators to confirm Elbridge Colby for Pentagon No. 3 post

    March 4, 2025

Editor’s Pick

  • Gold Price Surge Hits $3,385 Amid Trade Tensions

    April 21, 2025
  • Biden will address nation from Oval Office on decision to exit 2024 race

    July 23, 2024
  • EURGBP and EURCHF: EURCHF continues with pullback

    August 22, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock